27
September 2021
Alphamab Oncology Updated the Efficacy of a Phase II Clinical Study of KN046 Combined with Chemotherapy in the First-line Treatment of Pancreatic Cancer at CSCO Annual Meeting
the ORR was 50.0%, and the DCR was 95.5%,the 6-month progression-free survival rate was 62.3%.